Jason Zemansky

what gets you there? In terms of the potential friction points, is it just awareness? Do you see any pushback from payers?

Can you speak to some of the specific elements of patient behavior that gives you confidence at this point, specifically with regards to dynamics like compliance, discontinuations, prescription aba...

How has the DTC impacted awareness? Are you seeing more sort of interest from the patient side of things, more from the prescriber side of things?

what are some of the mechanics you're doing to practically move a patient onto treatment? What are some of the key systems you put in place?

what do you see as sort of the big levers there in terms of transitioning a patient who might be interested onto therapy

what are your expectations here in terms of restrictions, whether it's pulmonary exacerbations or something else